Evidence map›Paper›PMID 32008198›Full record

Trial reportInternational urology and nephrology2020

Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study.

Bruna Regis de Paiva, Marta Esgalhado, Natália Alvarenga Borges, Julie Ann Kemp, Gutemberg Alves, Paulo Emílio Corrêa Leite, Renata Macedo, Ludmila F M F Cardozo, Jessyca Sousa de Brito, Denise Mafra

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. The benefits of dietary fiber: the gastrointestinal tract and beyond.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bruna Regis de PaivaGraduate Program in Medical Sciences, Fluminense Federal University, Niterói, RJ, Brazil. bruna.regis.paiva@gmail.com.
Marta EsgalhadoGraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Natália Alvarenga BorgesGraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Julie Ann KempGraduate Program in Medical Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Gutemberg AlvesClinical Research Unit, Antônio Pedro Hospital, Fluminense Federal University, Niterói, RJ, Brazil.
Paulo Emílio Corrêa LeiteLaboratory of Bioengineering and in Vitro Toxicology, Directory of Metrology Applied to Life Science-Dimav, National Institute of Metrology Quality and Technology-INMETRO, Duque de Caxias, RJ, Brazil.
Renata MacedoGraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Ludmila F M F CardozoGraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, RJ, Brazil.ORCID http://orcid.org/0000-0001-8507-2369
Jessyca Sousa de BritoGraduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Denise MafraGraduate Program in Medical Sciences, Fluminense Federal University, Niterói, RJ, Brazil.
Universidade Federal Fluminense · BRInstituto Nacional de Metrologia, Qualidade e Tecnologia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD).

methodsA double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05 years, body mass index (BMI) 25.9 ± 5.42 kg/m

resultsAfter RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly.

conclusionThis preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.

Indexed as

DysbiosisGastrointestinal MicrobiomeRenal Insufficiency, ChronicCytokinesDouble-Blind MethodFemaleHumansImmunologic FactorsMaleMiddle AgedPrebioticsRenal DialysisResistant StarchTreatment OutcomeCytokinesImmunologic FactorsPrebioticsResistant StarchChronic kidney diseaseCytokinesHemodialysisInflammationResistant starch

Identifiers

PMID32008198
OpenAlexW3004050142

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.